Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab

Abstract: A 64‐year‐old woman, who had presented with a 30‐year history of refractory asthma, and been treated with anti‐allergic drug therapy, inhaled corticosteroids, a long‐acting beta‐agonist, and a long‐acting muscarinic antagonist. She had been characterized as an allergic, eosinophilic asthmatic. Although omalizumab was tried initially, it was found to be insufficient. We began treatment with benralizumab. The asthma symptom control and sinusitis were improved immediately. Benralizumab was effective for overlapping patient population following negative initial results with omalizumab.

ePDFPDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma Interasma - CME:Unlocking the Door to Asthma Control: Key Factors for Therapy Selection and Medication Management https://t.co/CiCJQvIgF9
6hreplyretweetfavorite
Interasma RT @EAACI_HQ: Read this article! RNA‐specific toll-like receptors #TLR are important in immunity against various pathogens but an inadequat…
6hreplyretweetfavorite
Interasma RT @worldallergy: Top story: This Is Why Food Allergies Are on the Rise, According to Experts https://t.co/oySQs4f4jq, see more https://t.c…
6hreplyretweetfavorite
Interasma RT @worldallergy: WAO Tweeted Times https://t.co/1tA4uy3LDq - top stories by @ARIAGuideline, @Interasma
6hreplyretweetfavorite
Interasma RT @worldallergy: Top story: POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Heal…
6hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma